Home > Insider Trading > Filing (0001035267-21-000127)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1035267	Intuitive Surgical Inc	ISRG	Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)	770416458

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1277620	H Craig Barratt	1020 Kifer Road Sunnyvale CA 94086		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-07-23	1,275	$161.27	1,275	No	4	M	Direct
Common Stock	Disposition	2021-07-23	1,275	$967.20	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2021-07-23	1,275	$0.00	1,275	$161.27

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2023-04-25	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,981	Indirect	by Trust

Footnotes

These shares were exercised and sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on March 8, 2022.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $963.28 to $975.41,inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.